Technology Platform
ADC Ideas' unique antibody introduction platform technology
Off-the-shelf universal NK products, full-factor cell culture, NK cells from peripheral blood
Antibody-cell conjugation technology
Antibody conjugation rate >90%, high stability
1 donor supports over 200 human doses
conditioned NK cell platform technologylity
Activation of special factors
Immune domestication culture
Enhanced expression of activation receptors
Potentiated in vivo cytotoxic activity of the trained NK cells
Antibody-directed NK cell connector platform technology
Bifunctional molecules
Guide NK cells to target tumor cells
Utilize endogenous NK cells
Combine with universal NK cells
R&D team
Ph.D. in Chemistry from Peking University; Postdoctoral researcher at Vanderbilt University, USA; Expert of Zhejiang Province's "Thousand Talents Program"; Leading Talent of Hangzhou 5050 Plan (Category A) and 521 Talent.
Former Chief Scientist at Enanta (NASDAQ listed) and Director of Chemistry at Ambrx (NASDAQ listed).
One of the principal inventors of the novel anti-hepatitis C drug Viekira Pak.
Global leader in ADC and renowned expert in Antibody-Cell Conjugate (ACC) NK cells.
Copyright2026 英百瑞（杭州）生物医药股份有限公司 All Rights Reserved. 浙ICP备2026093145号 KC Network Technology Support
